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Although the name for cancer as a disease was coined 
by ancient Greeks and Persians, and in spite of billions 
of euros, dollars, and other currencies invested in cancer 
research, the disease remains a major killer, particularly 
in Western countries (1). Over half of anticancer drugs, 
including acetogenins, alkaloids, and terpenes, are de-
rived from natural products, especially from the plant 
kingdom (2-6). Annonaceous acetogenins (ACGs) in-
clude a series of natural products isolated from Annon-
aceae plants. ACGs are white, waxy derivatives of long-
chain (C35 or C37) fatty acids, characterized by a long 
aliphatic chain bearing a terminal methyl substituted 
α, β –unsaturated γ-lactone ring with one-, two- or three 
tetrahydropyran (THP) rings (5). ACGs are a likely source 
of potential drugs as they exhibit various biological ac-
tivities such as cytotoxic, antitumor, antiparasitic, pesti-
cidal, pisicidal, antihelmenthic, antiviral, antimicrobial, 
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and immunosuppressive activities. They are known to 
be powerful inhibitors of complex I (NADH: biquinone 
oxidoreductases) in the mitochondrial electron trans-
port system. ACGs are also potential inhibitors of NADH 
oxidase in the plasma membranes of cancer cells and 
induce apoptosis by depleting ATP levels and arresting 
the cell cycle at the G1 phase (7). Desacetyluvaricin is an 
acetogenin isolated from Rollina mucosa, a tree found 
widely in tropical America (8). The fruit of this plant, 
commonly known in Mexico as “anonillo,” “anonita del 
monte,” and “cherimoya,” is edible, and is utilized in folk 
medicine as a therapeutic agent (9). Hepatocellular car-
cinoma (HCC), which accounts for 90% of primary liver 
cancer, is the third largest cause of cancer deaths world-
wide, particularly in Africa and Eastern Asia. Mechanisms 
involved in the development of HCC are difficult to elu-
cidate. Among various factors involved, research has re-
ported that a particular Hepatitis B viral X protein (HBx) 
or Hepatitis C viral core proteins induce HCC without 
other oncogenic alterations in murine models (10) by ac-
tivating NF-κB and AP-1 (11). 
Hepatocellular carcinoma may progress through inacti-
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repression) of the p53 tumor suppressor. HBx represses 
the transcription of the human p53 gene through the 
E-box element (12, 13). As the p53 protein binds and re-
presses the HBV enhancer/X promoter, HBx repression 
of the p53-promotor triggers a positive response that 
further represses p53 expression (14). Beside reciprocal 
transcriptional repression, HBx and p53 can inhibit each 
other by direct protein-protein interaction. The balance 
of the reciprocal inhibition between these two proteins 
may play a decisive role in the development of HBV-relat-
ed malignancies. In their paper published in this issue, 
He and colleagues have tested the antitumor activity of 
desacetyluvaricin using the Hepg2.2.15 cell line. Flow cy-
tometry analysis revealed a higher expression of p53 in 
desacetyluvaricin-treated cell lines when compared to 
untreated cell lines (15). The increase of p53 in the pres-
ence of desacetyluvaricin is very promising and may 
open new avenues for the therapeutic intervention of 
hepatocarcinoma. 
Another interesting aspect of desacetyluvaricin’s ac-
tivity that He and colleagues discovered is its effect on 
Toll-like receptors (TLRs). TLRs may promote tumor pro-
gression by acting directly on cancer cells, resulting in 
increased tumor cell–endothelial cell adhesion, tumour 
cell–extracellular matrix adhesion, and tumor cell–extra-
cellular matrix invasion through  NF-κB-mediated upreg-
ulation of β-1 integrin. Additionally, reports have dem-
onstrated that TLR signaling pathways play a key role in 
activating stem-cell/progenitor proliferation and con-
version to cancer-stem-cell-based liver tumor formation 
(16). TLRs have also been found on tumor cells, but their 
role in these cells is still unclear. In some tumor types, 
TLRs promote tumor proliferation and survival, whereas 
in others TLR2, -3, and -9 are directly involved in apopto-
sis (17). In their paper, He et al. reported that the expres-
sion of TLR4 is upregulated in the presence of the drug 
desacetyluvaricin (15). Although they assume that in this 
context TLR4 helps to activate the innate and adaptive 
immune responses to tumors, one should not disregard 
the fact that TLR activation may be a double-edged sword 
with both antitumor and protumor consequences. It is 
therefore necessary to conduct comprehensive studies 
to assess the significance of TLR4 expression in tumor im-
munotherapy. Another aspect omitted from the He et al. 
study, and it would certainly draw additional interest to 
their work, is the potential effect of desacetyluvaricin on 
hepatocellular-cancer stem cells (18, 19). In conclusion, 
although the manuscript is rather preliminary, the ob-
servations made by He et al. underlines the importance 
of desacetyluvaricin and related compounds as potential 
leads for the development of new anticancer drugs.
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